GLP-3 (RT)
Metabolic Compound

GLP-3 (RT)

Retatrutide-like blendGIP/GLP-1/glucagon agonist

A research-grade triple-action peptide blend designed for studies on metabolic regulation, appetite signaling, and energy expenditure. Premium Research Peptide.

Dosage
Third-Party TestingIdentity, purity, and batch consistency reviewed by an independent lab.
$69.99
Bundle & Save
1
Estimated delivery Mon, May 11Sun, May 17
Free shipping on orders over $99
Free shipment protection · Lost, damaged, stolen — we replace it.
Overnight shipping available
Research use only. Not for human consumption. Sold exclusively for qualified research.

Similar research products

Based on the current compound category and related research focus.

Third-Party Testing

We use third-party testing to give you a clearer look at identity, purity, and batch consistency before a product reaches your lab. Our testing is done by Freedom Diagnostics.

We use HPLC and/or Mass Spectrometry to make sure the peptide is what it says it is, with a clear look at purity and any major impurities we would want you to know about.

This helps us understand how much actual peptide is in the vial, separate from things like water, salts, or counterions, so the batch information is more useful and honest.

We check for bacterial endotoxins because cleaner documentation matters, especially for researchers working with sensitive cell culture or in vivo settings.

Additional vials from the same lot can be compared against the primary sample, giving another layer of confidence that the batch is consistent from vial to vial.

Certificate of Analysis Documents

  • Latest
    99.41%
    Purity
    View
    Variant
    GLP-3 5mg
    Lot #
    B2104
    Labeled
    5mg
    Actual
    5.18mg
    Tested
    Mar 12, 2026
  • Latest
    99.62%
    Purity
    View
    Variant
    GLP-3 10mg
    Lot #
    B2105
    Labeled
    10mg
    Actual
    10.41mg
    Tested
    Mar 12, 2026

Compound Information

Reference details for molecular identification, handling conditions, and storage guidance.

Molecular Profile

Type
Triple-agonist peptide blend
CAS Number
2381089-83-2 (retatrutide)
Molecular Weight
4731.4 g/mol
Amino Acids
39 (modified)
Formula
C₂₂₁H₃₄₃N₅₂O₆₅
PubChem Database

Stability & Storage

  • Protect from light
  • Avoid repeated freeze-thaw cycles
  • Lyophilized (powder)
    -20°C/up to 24 months
  • Reconstituted
    2-8°C/use within 30 days

Clinical & preclinical references

Peer-reviewed studies referenced for educational purposes only. Not intended as medical advice or product claims.

New England Journal of Medicine

Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

2023 / PMID 37366315 / DOI 10.1056/NEJMoa2301972
View Source
Cell Metabolism

A unimolecular peptide that activates GIP, GLP-1 and glucagon receptors

2022 / PMID 35167822
View Source
Lancet Diabetes & Endocrinology

Glucagon receptor agonism for the treatment of obesity

2023
View Source
New England Journal of Medicine

Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

2023 / PMID 37366315 / DOI 10.1056/NEJMoa2301972
View Source
Cell Metabolism

A unimolecular peptide that activates GIP, GLP-1 and glucagon receptors

2022 / PMID 35167822
View Source
Lancet Diabetes & Endocrinology

Glucagon receptor agonism for the treatment of obesity

2023
View Source
New England Journal of Medicine

Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

2023 / PMID 37366315 / DOI 10.1056/NEJMoa2301972
View Source
Cell Metabolism

A unimolecular peptide that activates GIP, GLP-1 and glucagon receptors

2022 / PMID 35167822
View Source
Lancet Diabetes & Endocrinology

Glucagon receptor agonism for the treatment of obesity

2023
View Source
New England Journal of Medicine

Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

2023 / PMID 37366315 / DOI 10.1056/NEJMoa2301972
View Source
Cell Metabolism

A unimolecular peptide that activates GIP, GLP-1 and glucagon receptors

2022 / PMID 35167822
View Source
Lancet Diabetes & Endocrinology

Glucagon receptor agonism for the treatment of obesity

2023
View Source
New England Journal of Medicine

Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

2023 / PMID 37366315 / DOI 10.1056/NEJMoa2301972
View Source
Cell Metabolism

A unimolecular peptide that activates GIP, GLP-1 and glucagon receptors

2022 / PMID 35167822
View Source
Lancet Diabetes & Endocrinology

Glucagon receptor agonism for the treatment of obesity

2023
View Source
New England Journal of Medicine

Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

2023 / PMID 37366315 / DOI 10.1056/NEJMoa2301972
View Source
Cell Metabolism

A unimolecular peptide that activates GIP, GLP-1 and glucagon receptors

2022 / PMID 35167822
View Source
Lancet Diabetes & Endocrinology

Glucagon receptor agonism for the treatment of obesity

2023
View Source
Research Use Only

Important Research Notice

Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

Clinical trial data and research findings on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.

By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.